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Summary Of 89 samples of cancer cells from ovarian cancer patients primary cultures representative of the
cancer cell population could be established in 17. The clinical response to polychemotherapy was studied in
relation to the inhibition of thymidine uptake by the cultured cells. Cultures of each patient's tumour were
exposed to concentrations of the drugs the patients had been given for long enough to reproduce the area
under the curve (AUC) of the plasma levels resulting from in vivo dosage. Full agreement was observed
between the degree of thymidine uptake inhibition induced by at least one of the drugs administered to the
cultured cells and the degree of clinical response. This approach may prove useful in pharmacological studies
as a means of obtaining ovarian cancer cell populations representative of human tumours, even though the
number of tumours that can be successfully evaluated in vitro is still too small to serve as a sound basis for
prediction.
The question whether the clinical response of
cancer to chemotherapeutic agents can be predicted
with sufficient accuracy by in vitro tests has been
widely studied (Wilson & Neal, 1981; Salmon et al.,
1980). The data on ovarian cancer justify some
optimism for clinical applicability (Wilson & Neal,
1981; Alberts et al., 1980).
A point that has often been neglected and might
explain the failure of in vitro sensitivity tests is the
lack of correspondence between the concentrations
and exposure time of drugs used in vitro and their
disposition in patients. The pharmacokinetic
parameter that best estimates the exposure of
tissues to a drug is the area under the curve of
concentration versus time (AUC) (Rowland &
Tozer, 1980). We therefore compared in vitro
sensitivity and clinical response using drug
concentrations and exposure times calculated on the
basis of the reported AUC values found in patients
given the drug at doses commonly used for ovarian
cancer.
This paper reports the findings in a group of
patients entered in clinical protocols including a
group of drugs previously tested in vitro at
concentrations and for exposure times comparable
to the AUCs resulting from the same dosage in
patients.
Materials and methods
Patients
Of a total of 89 samples from either solid tumours
or ascites, 16 tumours had no viable cells as
detected by the dye exclusion test, and 34 ascitic
fluids did not contain cancer cells. Nine of the 39
remaining samples became infected and 7 were
contaminated by fibroblasts. Tests were carried out
in vitro on 23 samples (26%) but 6 patients were
treated with drugs different from those planned at
the time of the in vitro test. Thus the study was
performed on 17 patients with histologically-
confirmed ovarian carcinoma of serous-mucinous
type. Patients were informed that biopsies taken
would be processed for in vitro studies also. Nine
had still to start their first course of chemotherapy
while 8 were receiving a second course.
Biopsy material for the in vitro test was obtained
from primary surgery, from second-look
laparotomy or from ascitic fluid after paracentesis
under sterile conditions. Tumour volume was
evaluated by measuring 2 perpendicular diameters
of at least one mass by clinical examination (X-
radiography and ultrasound scanning).
In all patients admitted to the study, residual
tumour was evaluated after treatment. Complete
response (CR) was defined as the total
disappearance of tumour confirmed by laparoscopy;
and partial response (PR) as 50% reduction in the
volume of remaining tumour. Among PR we
included the disappearance of ascites when the in
vitro test was performed on cells from fluids. No
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change (NC) was indicated when the increase or
decrease in tumour size was <50%. Progression
(PG) was defined as an increase in tumour volume
of >50%. Response was measured after the first 3
cycles ofchemotherapy.
Clinical and in vitro results were compared only
at the end of the study.
Establishment ofcultures
Tumour biopsy specimens were collected in PBS
containing 10O Uml - penicillin and 100jgml-l
streptomycin (GIBCO Europe, Glasgow, Scotland)
and rapidly processed in the laboratory a few hours
after collection. Tissue was divided and fragments
were imprinted on prestained slides (Test
Simplets(RI, Boehringer, Mannheim GmbH, W.
Germany) to test the presence of cells spilled out
from connective tissue and to confirm gross
diagnosis.
Soft tissues from which cells were easily spilled
were then disaggregated by treating 2mm fragments
with 0.25% Trypsin 1:250 (Difco Laboratories,
Detroit, Michigan, U.S.A.) in PBS without Ca2+
and Mg2+ for 30min at 37°C with stirring. Hard
tumours from which very few cells could be
recovered were minced carefully into very small
fragments then treated for 1 h at 37°C with
collagenase. Collagenase Type 1 (SIGMA Chemical
Company, St. Louis, U.S.A.) was dissolved 0.1-
0.3% in Medium 199 without serum. The cell
suspensions were then washed and resuspended in
growth medium.
If the tumours were contaminated by RBC or
macrophages we used the method described for the
ascitic fluid. Ascitic fluid was collected in
heparinized bottles and centrifuged at 200g for 10
min to separate the cellular contents. After
resuspension in PBS a first microscopic check was
made. Suspensions containing RBC and
mononuclear cells were separated on a discontinous
gradient of 100% Ficoll-Hypaque (d= 1.077; MSL,
Eurobio, Paris) for 20min at 600g. The tumour
cells in the upper layer of the gradient were then
freed of macrophages by adhesion (Mantovani et
al., 1979). In a few cases when a large number of
lymphocytes was present, a second gradient (75%
Ficoll-Hypaque in PBS layered on 100% Ficoll-
Hypaque) was prepared to separate cancer cells
from lymphocytes. After this step ascitic cells were
resuspended in growth medium.
At this stage viability was tested by dye
exclusion. The morphology of these preparations is
reported in Figure 1; they consisted mainly of nests
of cells. Preparations heavily contaminated by
stromal elements were discarded. Since a parallel
flow cytometry study was under way of the pattern
of DNA distribution in this type of culture, it was
anticipated that the number of diploid cells relative
to the aneuploid population would decrease with
time in our culture conditions. A rough cell count
was made of these clusters without attempting to
separate the single cells. Subsequent cultures could
in fact be established from these nests of cells. and
any attempt to disaggregate them resulted in loss of
viability.
Only suspensions with >70% viable cells were
then seeded at 3.5 x I05 viable cells ml - per well in
multiwell tissue culture plates (Linbro-Flow
Laboratories, Irvine, U.K.). Medium 199 was
supplemented with 15% FCS, 2mM glutamine, 6%
MEM essential aminoacid stock solution, 3% stock
solution of MEM vitamins (all purchased from
Flow Laboratories, Irvine, U.K.) and 20mM
HEPES (Merck, Darmstadt, W. Germany).
The pH was 7.2 in air, with osmotic pressure
maintained at 285 + 10 mosmol.
Drugs
Cell cultures from each patient were treated with
the drugs given to the patients. Concentrations and
contact times with cells were defined starting from
the plasma AUC measured in patients after a
similar schedule of adminstration. The kinetic data
and the concentrations selected for in vitro studies
are summarized in Table I.
Our problem encountered was the difficulty of
using cyclophosphamide (CY) in vitro because this
drug requires metabolic activation in vivo. The
kinetics of activation and the rates of conversion of
each metabolite to the next are still poorly defined,
but it is well known that liver-inducing drugs
strongly modify CY activation (Alberts & van
Daalen Wetters 1976; Donelli et al., 1976; Field et
al., 1972). Since several of the metabolites are
cytotoxic, we felt it was unrealistic to administer
compounds that become activated in vitro at a fixed
rate not comparable with in vivo activation. Even
less satisfactory would have been to use one of the
actual active metabolites. The problem was
provisionally overcome by using another alkylating
agent active in vivo, viz. L-phenyl-alanine mustard
(L-PAM). The feasibility of using this agent was
supported by the fact that L-PAM induces the
same frequency of response in ovarian tumours as
CY (Bagley et al., 1972). CY is preferred in vivo,
however, because of its lower toxicity.
In vitro treatment
Cells were exposed to drugs after -72h of culture
when the nests of cancer cells became well spread
out and any debris could be washed out. Each drug
was dissolved in fresh growth medium and left in
contact with cells for the time given in Table I;DRUG SENSITIVITY OF OVARIAN CANCER 63
Figure la 150 x H.E. Ovarian carcinoma-epithelial mass.
Figure lc 150 x (phase contrast) Clusters of epithelial cells
adhering in culture.
Figure lb 150 x (phase contrast) Cluster of epithelial cells
after separation.
Figure Id 150 x (phase contrast) Epithelial clusters at
confluence in culture.
Table I Plasma pharmacokinetics in cancer patients given chemotherapy and time/concentration
exposure in vitro of cells from patients (see text for abbreviations)
In vitro exposure
Plasma pharmacokinetics ofcells
Mean drug Drug
Drug, route AUC Time concentration Time concentration
and dose pugml-1*min (min) ,igml- *min-1 (min) igml-
HMM(1) 95-1438 1440 0.06-1.00 1440 0.07-0.7
oral 120-300mgmin 2
ADM(2-3)
i.v. 60mgm-2 77.4 1440 0.05 1440 0.05
1-PAM(4)
i.v. lomgm-2 24.6 60 0.41 60 0.4
5FU(5)
i.v. shot 8.5-12mgkg-1 1285 60 21.4 60 20
cis-DDP(6)
i.v. infusion 1 h 50mgm-2 3510 1380 2.5 1440 0.15-10
(1) D'Incalci et al., 1978.
(2) Benjamin et al., 1977.
(3) Piazza et al., 1980.
(4) Brox et al., 1979.
(5) MacMillan et al., 1978;
(6) Gormley et al., 1979.64 L. MORASCA et al.
during the same time controls were exposed to fresh
medium. After that cultures were drained, washed
in PBS and filled with fresh growth medium. This
recovery state was maintained for 72h and [3H]-dT
incorporation was measured over the final 6h by
addition of 0.5uCiml-1 of [3H]-dT (Spec.Act.
1.9CimM-1; Radiochemical Centre, Amersham,
England) to each well containing 1ml of growth
medium. At the end of the incubation cells were
washed twice in PBS, lysed by 1% sodium dodecyl
sulphate (SDS) and counted in a toluene-based
phosphor with a Packard Tricarb 3400 scintillator.
Statistical analysis
Controls and each treatment group comprised 8-10
replicate cultures. Dunnett's test was performed
using a Hewlett-Packard 85 computer. Limits of
significance were set at P<0.01. For ease of
comparison only significant inhibitions of uptake
are reported, as percentages of the control values.
Treatment regimes
Patients without previous therapy were treated in 6
cases with the combination adriamycin (ADM)
(50mgm-2 i.v. on Day 1), CY (70mgm-2 per day
p.o. on Days 1-14) and hexamethylmelamine
(HMM) (I50 mgm 2 per day p.o. on Days 1-14)
every 28 days; 2 patients were treated with the
combination ADM (50mgm2 i.v. on Day 1), cis-
DDP (50mgm-2 i.v. on Day 1) and CY
(70mgm-2 per day p.o. on Days 1-14) every 28
days. Two of the patients receiving a second course
of therapy were treated with ADM+CY+HMM
and a third with ADM +DDP+CY under the
same dose and schedule conditions as the first
course. Two patients were treated with
polychemotherapy comprising ADM (50mgm 2
i.v. on Day 1), cis-DDP (50mgm-2 i.v. on Day 1)
and HMM (150mgm-2 per day p.o. on Days 8-21)
every 28 days. Two patients were treated with the
combination CY(150mgm2 per day on Days 1-14),
HMM (150mgm-2 per day on Days 1-14),
methotrexate (MTX) (40mgm2 i.v. on Days 1 and
8) and 5-fluorouracil (5-FU) (600mgm-2 i.V. on
Days 1 and 8) every 28 days. One patient was
treated with CY (150mgm-2 per day on Days 1-14),
cis-DDP (50mgm-2 on Day 1), MTX (40mgm-2
i.v. on Days 1 and 8) and 5-FU (600mgm2 i.v. on
Days 1 and 8) every 28 days. One patient was
treated with CY alone (100mgm-2 per day p.o.)
indefinitely.
Results
The drugs significantly inhibiting [3H]-dT uptake in
vitro are indicated in Table II for each of the 9
patients' tumours on their first course of
chemotherapy. The chemotherapeutic regimens and
the clinical responses are also given. Of the 9
patients 2 had a CR (confirmed by laparatomy), 3
obtained a PR, 3 were unchanged (NC) and one
progressed (PG). No discrepancies were recorded
between the level of response in vivo and the
percentage ofinhibition in vitro.
Table III reports the findings in 8 patients
receiving a second course of treatment when they
had become resistant to L-PAM or CY. The 2
patients in this group whose tumours were sensitive
in vitro (C.B. and F.E.) did not obtain a PR of
their tumour mass but ascitic fluid disappeared.
Since in these cases we measured the in vitro
sensitivity of cells separated from ascitic fluid, it
seemed reasonable to consider the disapperance of
ascitic fluid as a counterpart of the sensitivity
recorded in vitro.
In a few cases, when there was enough biopsy
material, we also investigated whether the
combination of drugs proposed for in vivo studies
was more effective than the combined drugs in
vitro. The tumour of patient C.G. (Table II) was
insensitive to the combination of ADM+L-
PAM+cis-DDP at the concentrations and times of
exposure given in Table I. Similarly, for the cells of
patient S.C. (Table III) the same combination of
agents was inactive in vitro. In contrast, patients
R.A. (48) (Table II) and C.B. (Table III) gave
comparable in vitro inhibition after treatment with
either the combination or the individual drugs.
Discussion
For all 17 patients studied the degree of clinical
response compared well with the extent of
inhibition induced in vitro by at least one of the
drugs administered. This "full agreement" has a
lower confidence limit of 80% (P=0.05) and is
sufficient to demonstrate a correlation between the
degree of clinical response and an effect of the drug
on the cancer cells propagated in vitro.
In 4 patients the in vitro association of all the
drugs administered was tested and the response
again agreed with the clinical data. Thus in vitro
treatment of cancer cells with drug concentrations
comparable to the plasma levels attained in patients
after therapeutic doses gives reliable results, though
several problems have still to be resolved relating to
drug metabolism and protein binding.
The efficacy of anticancer agents in ovarian
cancer patients was recently studied by an in vitro
clonogenic assay with a predictive accuracy of 73%
for sensitivity and 100% for resistance (Alberts et
al., 1981). On primary cultures the correlation was
positive in all 8 patients receiving a first course ofDRUG SENSITIVITY OF OVARIAN CANCER 65
Table II Correlation of clinical response with growth inhibition of ovarian carcinoma cells in vitro by the
same drugs* for patients without previous therapy
Patient Inhibition
(age) Drugs [3H] dT Combination Clinical
RefJ no. Histology tested uptake chemotherapy response
R.A.(48) Serous ADM NS ADM+CY+HMM CR
2797 adenocarcinoma HMM 55
L-PAM 32
ADM+L-PAM+HMM 38
R.A.(41) Serous HMM 32 ADM+CY+HMM PR
2434 adenocarcinoma L-PAM NS
ADM NS
M.L.(56) Ascitic fluid ADM 37 ADM+CY+HMM PR
2892 from serous L-PAM NS
adenocarcinoma HMM NS
N.M.(55) Serous-mucinous ADM 45 ADM+CY+DDP PR
3107 adenocarcinoma L-PAM NS
DDP NS
G.V.(44) Serous ADM NS ADM+CY+HMM NC
2442 adenocarcinoma L-PAM NS
HMM NS
C.G.(57) Serous ADM NS ADM+CY+DDP NC
2927 adenocarcinoma L-PAM NS
DDP NS
ADM+L-PAM +DDP NS
S.A.(72) Mixed ADM NS ADM +CY+HMM NC
2807 adenocarcinoma L-PAM NS
HMM NS
T.M.(47) Ascitic fluid ADM NS ADM+CY+HMM PG
2726 from serous L-PAM NS
adenocarcinoma HMM NS
T.D.(21) Serous ADM 78 ADM+CY+HMM CR
2725 adenocarcinoma L-PAM NS
HMM NS
NS =not significant (P=0.01).
*Substituting L-PAM for CY in vitro.
chemotherapy, but only in 4/7 receiving a second
course (Wilson & Neal, 1981). In neither study was
the cell exposure to drugs matched to the real
exposure time in vivo since the clonogenic assay
exposes cells to each drug for 1 h (Alberts et al.,
1981) and the primary culture assay to each agent
for 48h (Wilson & Neal, 1981).
Among the drugs we tested adriamycin was
certainly the least affected in terms of cell exposure
time. However, pharmacokinetic measurements in
plasma show that exposure to the drug for 30min,
calculated from the plasma AUC, is at 0.3ugml-1
(Piazza et al., 1980). This may be correct if we take
into account only the distribution phase, but to
assess the entire effect of an adriamycin dose we
must consider the 24h exposure that covers the 3
phases of plasma level decay. In this case the
concentration calculated from the AUC is
0.05 ,gml-l (Benjamin et al., 1977) and is the time
per concentration we used in this study.
In the case of HMM however 24h exposure in
vitro is critical not only because its decay in plasma
covers a 24h period (D'Incalci et al., 1978) but also
because the in vitro cytotoxicity of this drug is time-
dependent (D'Incalci et al., 1980; Rutty & Abel,
1980). No information is available on cis-DDP
protein binding and its active form in plasma, so
data were adapted in the light of available
information (Gormley et al., 1979). For L-PAM
and 5-FU a 1 h exposure was indicated (Brox et al.,
1979); MacMillan et al., 1978). The method of
assessing.the effect of drugs in vitro is based on our66 L. MORASCA et al.
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previous experience in similar settings. Cancer cells
were morphologically identified in Rose chambers
(Morasca et al., 1979) so that relations between the
in vivo and in vitro effects of anticancer drugs could
be followed during treatment.
From studies of mouse osteosarcoma (Morasca
et al., 1974), mammary carcinoma in the C3H
mouse (Morasca et al., 1976) and human ovarian
cancer (Morasca et al., 1980), we concluded that
not only had in vitro treatment to be matched to
the real availability of drugs in vivo, but also since
cells developed symptoms of toxicity over time, the
most reasonable approach was to evaluate an end-
point of a well-matched interval after treatment.
For morphological scoring this was 120h (Morasca
et al., 1980).
However, morphological scoring as performed
previously was extremely time-consuming so we
tried other methods. Incorporation of [3H]-dT after
72h recovery was used in parallel with
morphological scoring in a small group of ovarian
cancer patients to compare the effects of different
times of exposure of cells to drugs (Morasca et al.,
1979). Since the findings overlapped, we adopted
[3H]-dT incorporation as a marker of viability. This
approach has already been used by other groups as
reviewed by Von Hoff & Weisenthal (1980) and its
limitations did not apparently affect our data,
probably because we did not test the acute effect of
treatment but the delayed effect after 72h recovery.
Though the data presented here are in full
correlation, it must be borne in mind that there can
be no general extrapolation to other tumours or
drugs. Ovarian cancer grows easily in culture and in
aneuploid tumours the cytofluorographic peak of
the diploid population decreases in time in
proportion to the aneuploid population
(unpublished data). This may not be the case for
other tumours. In terms of drug concentrations to
be used we have already mentioned our limited
knowledge of free and protein-bound cis-DDP. For
other drugs, the 72h recovery we used may not be
the optimal interval for evaluating [3H]-dT uptake.
In addition the conditions for performing this
kind of experiment are closely dependent upon the
amount of tumour tissue available and of cancer
cells present in the sample (many ascitic fluids
contain only enough cells for diagnosis). Thus, our
experience does not necessarily imply that this is
the best method of predicting response to
chemotherapy. It does, however, exploit human
ovarian cancer cells from real clinical situations of
sensitivity or resistance, for the study of drug
associations, new drugs, mechanisms of action, and
development of resistance in a morphologically and
biochemically favourable tissue culture system.
This work was supported by CNR Contract "Controllo
della Crescita Neoplastica" No. 81.01403.96.
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